![]() |
市場調査レポート
商品コード
1540824
マイクロバイオームシーケンスサービス市場レポート:技術、調査タイプ、ラボタイプ、用途、エンドユーザー、地域別2024-2032Microbiome Sequencing Services Market Report by Technology (Sequencing by Synthesis, Sequencing by Ligation, Pyrosequencing, Sanger Sequencing, and Others), Research Type, Laboratory Type, Application, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
マイクロバイオームシーケンスサービス市場レポート:技術、調査タイプ、ラボタイプ、用途、エンドユーザー、地域別2024-2032 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2~3営業日
|
マイクロバイオームシーケンスサービス市場の世界市場規模は、2023年に22億1,930万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに99億7,930万米ドルに達し、2024年から2032年の間に17.6%の成長率(CAGR)を示すと予測しています。大衆の間で感染症が増加していること、FMTを含むマイクロバイオームベースの治療法への傾倒が高まっていること、獣医療におけるマイクロバイオームシーケンシングの採用が拡大していることなどが、市場を推進している主な要因の1つです。
マイクロバイオームシーケンスサービスは、人体を含む様々な環境に生息する微生物群集の解析を伴う。これらは、ヒトの腸、土壌、水などの特定の生態系に生息する多様な微生物を同定・分析するために設計された専門的な手順です。高度なデオキシリボ核酸(DNA)配列決定技術を用いて微生物の遺伝物質を解読することで、研究者やヘルスケア専門家はこれらの微生物群集の構成、多様性、機能を理解することができます。
大衆の間で感染症が増加していることが、宿主と病原体の関係を研究するためのマイクロバイオームシーケンスサービスの需要を喚起しており、世界中でそのサービスに対する需要が高まっています。さらに、治療の有効性と安全性を確保するために正確なマイクロバイオームプロファイリングが必要となる、糞便微生物叢移植(FMT)を含むマイクロバイオームベースの治療への傾斜が高まっていることも、市場の成長を後押ししています。これとは別に、動物の健康状態の把握、疾病予防、家畜生産の改善を目的とした獣医療におけるマイクロバイオームシークエンシングの採用拡大が、市場にプラスの影響を与えています。また、製薬業界の拡大により、マイクロバイオームデータを利用して新薬、特に消化器疾患をターゲットとした新薬を開発する動きが活発化しており、これが市場の成長に寄与しています。さらに、データ駆動型の意思決定に依存する精密農業の採用が増加していることも、市場の成長を後押ししています。
個別化医療と治療の増加
個別化医療の増加に伴い、個々の患者に合わせた治療や介入を提供するためのマイクロバイオームシーケンスサービスの需要が増加しています。マイクロバイオームシーケンスサービスに対する需要の原動力の1つは、各個人のマイクロバイオームがユニークであり、治療に対する反応に大きな影響を与える可能性があるという認識です。プロバイオティクスレジメンの最適化であれ、食事療法の推奨の指針であれ、薬剤の有効性の予測であれ、マイクロバイオームデータは不可欠です。患者やヘルスケアプロバイダーは、より良い治療結果を達成し、副作用を最小限に抑え、全体的なウェルネスを向上させるために、こうした洞察をますます求めるようになっています。その結果、個別化医療が現代ヘルスケアの中心的な考え方となりつつあり、マイクロバイオームシーケンスサービスに対する需要が高まっています。
消費者の意識の高まりとウェルネス
健康とウェルネスにおけるマイクロバイオームの役割に対する消費者の意識は着実に高まっています。人々は健康に対してより積極的になり、健康増進のためにマイクロバイオームを最適化する方法を求めるようになっています。この動向を後押ししているのが、腸内細菌叢に関する知見を個人に提供する消費者直販のマイクロバイオーム検査キットです。消費者はマイクロバイオームと様々な健康面との関連性をより深く理解するようになり、詳細な分析と個人に合わせた推奨を得るためにマイクロバイオームシーケンスサービスを利用するようになっています。このような一般消費者の関心の高まりは、マイクロバイオームシーケンスサービスに対する需要を後押ししています。個人は、より健康的なマイクロバイオームを促進するために、十分な情報に基づいたライフスタイルの選択や食生活の調整を行おうとしているからです。
高まる規制要件と品質保証
ヘルスケア、農業、食品安全における規制機関は、安全性と品質基準の確保におけるマイクロバイオームデータの重要性を認識しつつあります。例えば、食品業界では、潜在的な病原体や腐敗生物を特定することで食品の安全性をモニタリングし改善するためにマイクロバイオームシーケンスが利用されています。同様に、農業の規制機関は、持続可能な農業慣行を確保するためにマイクロバイオーム評価を要求することがあります。これらの規制を遵守するためには、高品質な基準を維持するためにマイクロバイオームシーケンスサービスを利用する必要があり、規制要件を満たし、製品の安全性を確保しようと努める企業や組織からの一貫した需要につながっています。
The global microbiome sequencing services market size reached US$ 2,219.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 9,979.3 Million by 2032, exhibiting a growth rate (CAGR) of 17.6% during 2024-2032. The increasing incidences of infectious diseases among the masses, rising inclination towards microbiome-based therapeutics, including FMT, and the growing adoption of microbiome sequencing in veterinary medicine are some of the major factors propelling the market.
Microbiome sequencing services involve the analysis of microbial communities that inhabit various environments, including the human body. They are specialized procedures designed to identify and analyze the diverse microorganisms living in a particular ecosystem, such as the human gut, soil, or water. They use advanced deoxyribonucleic acid (DNA) sequencing technologies to decode the genetic material of microorganisms, which allows researchers and healthcare professionals to understand the composition, diversity, and function of these microbial communities.
Increasing incidences of infectious diseases among the masses are catalyzing the demand for microbiome sequencing services for studying host-pathogen relationships, which lead to rising demand for its services around the world. Moreover, the rising inclination towards microbiome-based therapeutics, including fecal microbiota transplantation (FMT), that necessitates accurate microbiome profiling to ensure treatment efficacy and safety is favoring the growth of the market. Apart from this, the growing adoption of microbiome sequencing in veterinary medicine for understanding animal health, disease prevention, and improving livestock production is influencing the market positively. In addition, the expansion of the pharmaceutical industry is driving the use of microbiome data to develop novel drugs, particularly those targeting gastrointestinal diseases, which is contributing to the market growth. Furthermore, the increasing adoption of precision agriculture practices, which rely on data-driven decision-making, is bolstering the market growth.
Increase in personalized medicine and therapies
With the rising use of personalized medicine, there is a rise in the demand for microbiome sequencing services to offer tailoring treatments and interventions to individual patients. One of the driving forces behind the demand for microbiome sequencing services is the recognition that each microbiome of a person is unique and can significantly impact their response to treatments. Whether it is optimizing probiotic regimens, guiding dietary recommendations, or predicting drug efficacy, microbiome data is indispensable. Patients and healthcare providers increasingly seek these insights to achieve better treatment outcomes, minimize adverse effects, and enhance overall wellness. Consequently, the demand for microbiome sequencing services is rising as personalized medicine is becoming a central tenet of modern healthcare.
Rise in consumer awareness and wellness
Consumer awareness about the role of microbiomes in health and wellness has been steadily increasing. People are becoming more proactive about their health, seeking ways to optimize their microbiomes for improved well-being. This trend is driven by the availability of direct-to-consumer microbiome testing kits that provide individuals with insights into their gut microbiota. As consumers gain a better understanding of the connections between their microbiome and various health aspects, they are turning to microbiome sequencing services for in-depth analysis and personalized recommendations. This surge in interest from the public is propelling the demand for microbiome sequencing services, as individuals seek to make informed lifestyle choices and dietary adjustments to promote a healthier microbiome.
Growing regulatory requirements and quality assurance
Regulatory bodies in healthcare, agriculture, and food safety are increasingly recognizing the importance of microbiome data in ensuring safety and quality standards. For instance, in the food industry, microbiome sequencing is used to monitor and improve food safety by identifying potential pathogens or spoilage organisms. Similarly, regulatory agencies in agriculture may require microbiome assessments to ensure sustainable farming practices. Compliance with these regulations necessitates the utilization of microbiome sequencing services to maintain high-quality standards, leading to a consistent demand from businesses and organizations striving to meet regulatory requirements and ensure the safety of their products.
IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, research type, laboratory type, application, and end user.
Sequencing by Synthesis (SBS)
Sequencing by Ligation (SBL)
Pyrosequencing
Sanger Sequencing
Others
Sequencing by synthesis (SBS) dominates the market
The report has provided a detailed breakup and analysis of the market based on the technology. This includes sequencing by synthesis (SBS), sequencing by ligation (SBL), pyrosequencing, sanger sequencing, and others. According to the report, sequencing by synthesis (SBS) represented the largest segment. SBS is the fundamental technology behind microbiome sequencing services. It is employed to unravel the genetic makeup of microorganisms in a given sample. During SBS, DNA strands from the microbial community are broken down into their individual components and then precisely reconstructed. This process relies on the incorporation of fluorescently labeled nucleotides into the growing DNA strands, which emit distinct signals as they are added. These signals are detected and translated into the genetic sequence, which enables scientists to identify the types and quantities of microorganisms present in the sample. SBS is highly accurate and efficient, which makes it a cornerstone of microbiome analysis, with applications ranging from human health research to environmental monitoring.
Outsourced Research
Internal Research
Outsourced research holds the largest share in the market
A detailed breakup and analysis of the market based on the research type has also been provided in the report. This includes outsourced research and internal research. According to the report, outsourced research accounted for the largest market share. In the realm of microbiome sequencing services, research frequently encompasses an outsourced approach. This entails collaborating with external research partners or specialized service providers who possess advanced capabilities in microbiome analysis. These outsourced research endeavors are driven by the complexity and technical demands of microbiome studies. By leveraging the expertise and resources of established entities in this field, researchers can access cutting-edge sequencing technologies, bioinformatics tools, and domain-specific knowledge. This collaborative model fosters more comprehensive and insightful microbiome investigations, whether in the context of human health, environmental science, or agriculture, ultimately contributing to the advancement of knowledge in this burgeoning field.
Dry Labs
Wet Labs
Wet labs hold the largest share in the market
The report has provided a detailed breakup and analysis of the market based on the laboratory type. This includes dry labs and wet labs. According to the report, wet labs accounted for the largest market share. Wet labs are the physical spaces wherein the initial stages of microbiome sequencing occur. These labs handle the actual samples, perform DNA extraction, and prepare them for sequencing. Wet labs are equipped with state-of-the-art molecular biology instruments and techniques to ensure the integrity and quality of the genetic material from microbial communities. Scientists in wet labs use specialized protocols to isolate DNA, amplify specific regions of interest, and prepare sequencing libraries. These meticulously controlled procedures are essential to ensure accurate and reliable microbiome sequencing data. Once the sample preparation is complete, the processed samples are sent to sequencing facilities or dry labs for further analysis. Wet labs are the hands-on, experimental arm of microbiome research, where the journey from sample to data begins.
Shotgun Sequencing
Targeted Gene Sequencing
RNA Sequencing
Whole Genome Sequencing
Others
Shotgun sequencing holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes shotgun sequencing, targeted gene sequencing, RNA sequencing, whole genome sequencing, and others. According to the report, shotgun sequencing accounted for the largest market share. It is a powerful and comprehensive application of microbiome sequencing services. In this approach, the entire genetic material, or DNA, of a microbial community is sequenced without specifically targeting any genes or regions. This method provides a holistic view of the microbial diversity within a sample, which allows researchers to identify all the microorganisms present and gain insights into their functional potential. Shotgun sequencing is particularly useful for exploring unknown or complex microbiomes, as it does not require prior knowledge of the specific genes of interest. It is widely applied in environmental studies, such as soil and water microbiology, and has significant relevance in understanding the human gut microbiome's complexity and its implications for health. By elucidating the complete genetic makeup of microbial communities, shotgun sequencing contributes to a deeper understanding of their roles in various ecosystems and their potential applications.
Pharmaceutical and Biotechnology Companies
Research and Academic Institutes
Others
Pharmaceutical and biotechnology companies dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical and biotechnology companies, research and academic institutes, and others. According to the report, pharmaceutical and biotechnology companies represented the largest segment. These companies represent key end users of microbiome sequencing services. These companies leverage microbiome data to drive innovation in drug discovery, development, and therapeutic interventions. By partnering with specialized service providers, they gain access to cutting-edge sequencing technologies and expertise in microbiome analysis. This collaboration enables pharmaceutical and biotechnology companies to explore the intricate relationship between the human microbiome and health with the goal of identifying novel drug targets, biomarkers, and therapeutic candidates. Additionally, microbiome sequencing aids in the development of probiotics and microbiome-based therapies, which offer potential solutions for a range of medical conditions. As such, pharmaceutical and biotechnology firms play a pivotal role in translating microbiome research into tangible healthcare advancements, ultimately benefiting patients and advancing the field of life sciences.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest microbiome sequencing services market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The increasing knowledge about the advantages of early diagnosis and disease detection represents one of the primary factors driving the demand for microbiome sequencing services in the North American region. Moreover, the surging prevalence of colorectal cancer (CRC) is favoring the growth of the market in the region. Besides this, the growing geriatric population, that are more prone to develop severe medical conditions, is influencing the market positively in the region.
Asia Pacific is estimated to witness stable growth, owing to increasing investment in developing novel drugs, extensive research and development (R&D) activities, integration of advanced technologies, etc.
The leading companies are adopting the use of high throughput sequencing in microbiome sequencing services to enable the simultaneous analysis of numerous microbial samples, which facilitates large-scale studies and delivers high-resolution data on microbial community composition. They are also using metagenomics that allows researchers to sequence the DNA of an entire microbial community in a sample without isolating individual species and enables a holistic view of the microbiome. Moreover, key players are integrating artificial intelligence (AI) and machine learning (ML) into microbiome data analysis that help identify patterns, predict microbial interactions, and discover biomarkers associated with health or disease, which enhances the interpretability of complex microbiome datasets.
BaseClear B.V.
Clinical-Microbiomics A/S
Diversigen Inc (OraSure Technologies Inc.)
Merieux NutriSciences
Metabiomics Corporation (BioSpherex LLC)
Microbiome Insights Inc.
Microbiome Therapeutics LLC
Molecular Research LP
Molzym GmbH & Co. KG
Resphera Biosciences LLC
Shanghai Realbio Technology (RBT) Co. Ltd.
Zymo Research Corporation
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
In 2022, Diversigen Inc (OraSure Technologies Inc.) launched metatranscriptomic sequencing and analysis services for gut microbiome samples.